Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase ...
Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has named Vimal Patel, PharmD, as senior vice president of medical ...
InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...
Mild hidradenitis suppurativa is often treated with cycles of steroids and antibiotics that have adverse effects. Can an anti ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Applic ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss ...
Differentiating tunnel and abscess/inflammatory nodule recurrence refines surgical outcomes after wide excision in patients ...
Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1–3 doses/yr with strong efficacy; liquid balance ...
Dismissal of care priorities rather than cultural context is the greatest barrier to proper wound care among Latine patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback